2008
Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization
Pal L, Jindal S, Witt BR, Santoro N. Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertility And Sterility 2008, 89: 1694-1701. PMID: 18440515, PMCID: PMC2601677, DOI: 10.1016/j.fertnstert.2007.05.055.Peer-Reviewed Original ResearchConceptsNondonor IVF cyclesClinical pregnancyCycle cancellationLive birthsGonadotropin useIVF cyclesSpontaneous miscarriageOvarian reserve statusOvarian hyperstimulation resultsHigh gonadotropinsOvarian stimulationFertilization cyclesIVF outcomesOocyte yieldWorse prognosisRetrospective studyIVF centerImproved outcomesAggressive approachMAIN OUTCOMEPregnancyIVFHigher likelihoodBirthOutcomes
2004
Postthaw blastomere survival is predictive of the success of frozen–Thawed embryo transfer cycles
Pal L, Kovacs P, Witt B, Jindal S, Santoro N, Barad D. Postthaw blastomere survival is predictive of the success of frozen–Thawed embryo transfer cycles. Fertility And Sterility 2004, 82: 821-826. PMID: 15482754, DOI: 10.1016/j.fertnstert.2004.02.136.Peer-Reviewed Original ResearchConceptsEmbryo transfer cyclesFET cyclesBlastomere survivalImplantation rateTransfer cyclesFrozen-thawed embryo transfer cyclesClinical pregnancy rateTertiary care facilitySerum P levelsClinical pregnancyHCG administrationInfertile womenRetrospective studyInverse associationIVF unitPregnancy rateMAIN OUTCOMECare facilitiesPregnancySurvivalOutcomesEmbryo survivalLower survivalHigher survivalAdministration
1998
Malignancy may adversely influence the quality and behaviour of oocytes.
Pal L, Leykin L, Schifren J, Isaacson K, Chang Y, Nikruil N, Chen Z, Toth T. Malignancy may adversely influence the quality and behaviour of oocytes. Human Reproduction 1998, 13: 1837-1840. PMID: 9740435, DOI: 10.1093/humrep/13.7.1837.Peer-Reviewed Original ResearchConceptsMalignant diseaseMalignant disordersAge-matched patientsCell of originTubal infertilityIVF cyclesOvarian stimulationDefinitive treatmentCase seriesCertain malignanciesNeoplastic processPatientsComparable total numberMature oocytesMalignancyFertilization rateDiseasePotential fertilityApparent adverse influenceOocytesPoor qualityDisordersTotal numberAdverse influenceInfertility